All Videos

A collection of clinical insights on prurigo nodularis, exploring awareness and educational efforts as well as trends in treatment.

Larry Eichenfield, MD, discusses how fostering transparent communication with families affected by pediatric vitiligo involves addressing their concerns, setting realistic treatment expectations, providing emotional support, and empowering parents to be advocates for their children’s physical and emotional well-being.

Larry Eichenfield, MD, discusses how pediatric vitiligo can profoundly impact a child’s mental health, self-esteem, and social relationships, requiring a comprehensive care approach that includes psychological support, family counseling, and strategies to help children navigate peer interactions and build resilience.

Larry Eichenfield, MD, discusses how vitiligo manifests uniquely in children through its earlier onset patterns, rapid progression phases, specialized diagnostic challenges for developing skin, and modified treatment approaches that must carefully balance effectiveness with safety concerns for young patients.

Dustin Portela, DO, introduces the topic of Swift technology and how this microwave therapy is revolutionizing wart treatment by activating the immune system to fight off viral infections naturally.

Karan Lal, DO, MS, FAAD, discusses how building a collaborative care network between parents, caregivers, and school staff is crucial for successful management of pediatric atopic dermatitis through consistent treatment application, trigger avoidance, and emergency response planning.

A panelist discusses how treating pediatric atopic dermatitis requires special attention to age-appropriate therapies, family education, adherence challenges, and the impact on children’s quality of life, including sleep and social development.

Karan Lal, DO, MS, FAAD, discusses how physicians can distinguish pediatric atopic dermatitis from similar skin conditions through key clinical features such as characteristic rash distribution, intense itching, and family history of atopic diseases.

A panelist discusses how selecting the optimal laser device requires careful consideration of wavelength, pulse duration, and spot size to effectively target specific skin concerns while minimizing potential adverse effects.

Melodie Young, MSN, A/GNP-C, discusses how clinical and practical considerations, such as disease severity, patient preferences, and comorbidities, should guide the selection of treatment for prurigo nodularis, and emphasizes the importance of educating patients about the role of systemic therapies, addressing their concerns, and improving awareness of available treatment options.

Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of action—dupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31—and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.

Melodie Young, MSN, A/GNP-C, discusses how to effectively communicate with patients about managing itch in prurigo nodularis, offering practical tips such as setting realistic expectations, emphasizing the importance of consistent skin care routines, and exploring both pharmacologic and non-pharmacologic strategies to alleviate discomfort.

Melodie Young, MSN, A/GNP-C, discusses how diagnosing prurigo nodularis can be challenging due to its similarity to other pruritic conditions, and highlights the importance of recognizing key features and patient subtypes with increased prevalence to accurately differentiate it from conditions like eczema and psoriasis.

Panelists discuss how the efficacy data from the Effisayil 2 trial demonstrate that spesolimab significantly delayed the time to first GPP flare and reduced flare severity, highlighting its potential as an effective treatment for preventing life-threatening flares in GPP patients.

Panelists discuss how factors such as tumor size, location, patient age, and overall health guide the decision between surgical excision and nonsurgical treatments such as topical therapies or radiation for managing basal cell carcinoma (BCC) effectively.

Panelists discuss how the Effisayil 2 trial included diverse patient demographics across different spesolimab dose groups, with baseline characteristics such as age, disease severity, and history of GPP flares influencing the treatment outcomes and safety data.

Melodie Young, MSN, A/GNP-C, discusses how prurigo nodularis imposes a significant physical and mental burden on patients, with chronic itching, skin lesions, and emotional distress leading to a reduced quality of life and increased anxiety and depression.

Karan Lal, DO, MS, FAAD, discusses how to balance safety and efficacy considerations while promoting treatment adherence in young vitiligo patients, focusing on the unique challenges and monitoring requirements for this vulnerable population.

Karan Lal, DO, MS, FAAD, discusses how to optimize vitiligo management in pediatric patients through personalized treatment selection and age-appropriate counseling strategies that address both the physical and psychosocial aspects of the condition.

Karan Lal, DO, MS, FAAD, discusses how treatment approaches for vitiligo differ between adult and pediatric populations, with experts examining distinct patterns of care, therapeutic considerations, and clinical pearls specific to each age group.

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.

Panelists discuss how patients with atopic dermatitis face numerous obstacles to optimal care, including limited access to specialists, high treatment costs, inadequate insurance coverage, and the need for more effective long-term management options.